- Home
- RNP vs COLL Comparison
RNP vs COLL Comparison
Compare RNP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNP | COLL |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.9M | 1.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RNP | COLL |
|---|---|---|
| Price | $20.64 | $34.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $50.83 |
| AVG Volume (30 Days) | 115.9K | ★ 400.6K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.21 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $19.00 | $23.23 |
| 52 Week High | $22.99 | $50.79 |
Technical Indicators
Market Signals| Indicator | RNP | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 16.51 |
| Support Level | $19.90 | $34.30 |
| Resistance Level | $20.69 | $36.20 |
| Average True Range (ATR) | 0.28 | 1.59 |
| MACD | -0.16 | -0.70 |
| Stochastic Oscillator | 2.50 | 2.18 |
Price Performance
Historical ComparisonAbout RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.